Positioning and Indication of Sorafenib in the Treatment Algorithm and Real Practice Setting: Western and Eastern Approach – Asian Perspective

Lee, Jung Min; Han, Kwang Hyub

doi:10.1159/000315246

Cited by 13 publications

(12 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, sorafenib for advanced HCC is still not easy for Asian physicians to prescribe due to high costs [25,26,27]. For the management of advanced HCC, sorafenib has not yet been approved for reimbursement in most Asian countries due to a big burden on the national insurance budget.…”

Section: Treatment Strategies For Advanced Hccmentioning

confidence: 99%

“…There are still many options aside from sorafenib for the locally advanced stage based on experts’ opinions [23,24,25,26,27,28,29,30]. According to the treatment algorithm of Asia (Japan, Korea, and China), not only sorafenib but also many therapeutic options such as surgical resection, TACE, HAIC, and external radiation can be tried for the advanced stage.…”

Section: Treatment Strategies For Advanced Hccmentioning

confidence: 99%

See 1 more Smart Citation

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia

et al. 2011

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for 80% of victims worldwide. Screening programs improve the detection of early HCC and have a positive impact on survival, but the majority of HCC patients in Asia still present with advanced stage disease. The treatment outcomes of HCC are affected by multiple variables, including liver function, performance status of the patient, and tumor stage. Therefore, it is not easy to apply a multidisciplinary therapeutic approach for optimal management. At present, limited numbers of HCC patients are eligible for curative therapies such as surgery or ablation in Asia. Therefore, most patients are eligible for only palliative treatments. For optimal management, the treatment choice is guided by staging systems and treatment guidelines. Numerous staging systems have been proposed and treatment guidelines vary by region. According to the Barcelona Clinic Liver Cancer (BCLC) guideline based on evidence from randomized clinical trials, only transarterial chemoembolization (TACE) is recommended for intermediate stage HCC and sorafenib for advanced stage HCC. However, treatment guidelines from Asian countries have adopted several other therapeutic modalities such as a surgical approach, hepatic arterial infusion chemotherapy, external radiation, and their combinations based on clinical experiences for intermediate and advanced stage HCC. Although TACE is the main therapeutic modality in the intermediate stage, overall therapeutic outcomes depend on the tumor size. In the advanced stage, the prognosis depends on the tumor status, e.g. major vessel invasion or extrahepatic spread. Thus, a new staging system representing prognoses suitable for Asian HCC patients and a corresponding optimal treatment algorithm should be further investigated using evidence-based data, which will finally bring about an Asian consensus for the management of intermediate and advanced stage HCC.

show abstract

Section: Treatment Strategies For Advanced Hccmentioning

confidence: 99%

Section: Treatment Strategies For Advanced Hccmentioning

confidence: 99%

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Prevention is always the best strategy to reduce liver cancer, especially through hepatitis vaccination and aflatoxin removal campaigns [6] but little can be done once chronic disease is rampant. Few specific chemotherapeutic options are available for this cancer; one of these being sorafenib [7]. Therefore, new therapeutic approaches are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

et al. 2013

View full text Add to dashboard Cite

Chronic liver disease may result in a sequential progression through fibrosis, cirrhosis and lead, eventually, to hepatocellular carcinoma (HCC). Hepatic stellate cells (HSC) seem to be responsible for the fibrogenic response through the activation of an autocrine loop involving the chemokine receptor, CCR5. However, the role of CCR5 in HCC remains poorly understood. Since this receptor is also one of the main ports of entry for the human immunodeficiency virus (HIV), several CCR5 inhibitors are being used in the clinic to reduce viral load. We used one of these inhibitors, maraviroc (MVC), in a mouse model of diet-induced HCC to investigate whether this intervention would reduce disease progression. Animals treated with MVC on top of a normal control diet did not present any evidence of toxicity or any morphological change when compared with non-treated mice. Animals treated with MVC presented higher survival, less liver fibrosis, lower levels of liver injury markers and chemokines, less apoptosis, lower proliferation index, and lower tumor burden than their counterparts receiving only the hepatotoxic diet. In addition, MVC inhibits HSC activation markers such as phosphorylation of p38 and ERK, and increases hepatocyte survival. This study suggests that MVC, a well tolerated and clinically characterized drug, may be used as a preventative treatment for HCC. Clinical studies are needed to demonstrate the efficacy of this drug, or other CCR5 inhibitors, in patients with high risk of developing HCC.

show abstract

“…For small HCC, outcomes following RFA and hepatic resection are comparable (23). Although sorafenib has been shown to be effective in non-resectable HCC, its exact role in the algorithm of HCC management needs further studies (24). The overall median survival between the two groups showed minor advantage for patients in Atlantic Canada.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Cancer Care for Hepatocellular Carcinoma at Two Tertiary-Care Referral Centers from High and Low Endemic Regions for Viral Hepatitis

Alsohaibani¹,

Porter²,

Al-Ashgar³

et al. 2010

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

Positioning and Indication of Sorafenib in the Treatment Algorithm and Real Practice Setting: Western and Eastern Approach – Asian Perspective

Cited by 13 publications

References 67 publications

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

Comparison of Cancer Care for Hepatocellular Carcinoma at Two Tertiary-Care Referral Centers from High and Low Endemic Regions for Viral Hepatitis

Contact Info

Product

Resources

About